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OBJECTIVES: The primary objective of this study is to
estimate the number of hip/knee replacements performed
in the nation as well as to produce synthetically derived
estimates for Ohio. These estimates were then used for
the estimation of the economic burden associated with
these arthritis related surgeries. METHODS: The 2000
National Hospital Discharge Survey (NHDS) was utilized
to estimate the number of hip/knee replacements per-
formed in the nation. The ICD-9-CM procedure codes
used to identify patients are ICD-9-CM 81.51 (total hip
replacement) and 81.54 (Total/partial knee replacement).
The NHDS recorded up to four ICD-9-CM procedures
for each discharge. Since the main purpose of this study
was to estimate the burden of arthritis-related surgeries,
all four procedures recorded for each patient were con-
sidered for the identiﬁcation of arthritis-related surgery.
Then, the total number of hip/knee replacements in Ohio
was estimated by applying age and sex distributions based
on the U.S. census 2000. Since the NHDS does not
include cost information on hospital discharges, diagno-
sis related group (DRG) reimbursement was used to
approximate the total hospital charges. RESULTS: In the
United States, approximately 9.6 billion dollars were used
for 439,833 hip and knee replacement surgeries in the
year 2000. In Ohio, approximately 407 million dollars
were spent for 18,731 hip and knee replacement surg-
eries. CONCLUSIONS: The estimated cost for joint
replacements alone was nearly $10 billion in the United
States during the year 2000. The total cost of joint
replacements will be much higher if we include pre and
post-operation care.
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OBJECTIVES: Rheumatoid arthritis (RA) is an important
cause of admission to UK hospital wards, although few
estimates of the cost implications of RA in the hospital
sector exist in the literature. This study presents a method
of estimating the hospital burden of RA in England.
METHODS: The CHKS hospital dataset contains aggre-
gated, anonymised information on diagnosis, hospital
experience, and patient demographics for over 80 million
episodes in the UK. The CHKS sample, which covers
approximately 55% of UK hospital admissions, was used
to describe and assess the impact of RA-related episodes
in England. Patients with RA (ICD-10 codes M05, M06)
as a primary or secondary diagnosis were analysed 
for comorbidities, procedures (identiﬁed using OPCS-4
codes), length of stay, and for repeat admissions during
the year. RESULTS: We identiﬁed 10,425 unique patients
admitted with primary RA in 2001. These patients had a
total of 17,395 separate episodes, 42% of which were day
cases. Mean inpatient length of stay was 6.9 days, result-
ing in 70,305 occupied bed days. At least 1 invasive pro-
cedure was undertaken in 74% of episodes. While these
were mainly injections and infusions, there were 1650
joint replacements. From a resource use perspective, the
10% of procedures involving joint replacement accounted
for 22% of total occupied bed days. Forty four percent
of patients with a primary RA episode also had primary
RA episodes in the previous 4 years. A further 15,640
unique patients with secondary RA were also identiﬁed,
having a total of 28,979 episodes. CONCLUSIONS:
Each year, there are over 25,000 unique patients with a
RA related episode in England. This represents a sub-
stantial resource burden in the National Health Service
(NHS). An effective and well-tolerated agent, such as an
anti-TNF therapeutic, would help reduce the burden on
an already overstretched healthcare sector.
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OBJECTIVES: A local clinical trial showed that celecoxib
therapy was comparable in efﬁcacy to diclofenac plus
omeprazole in preventing recurrent gastrointestinal bleed-
ing in high-risk patients. The objective of the present
study is to evaluate the economic impact of celecoxib
therapy versus diclofenac plus omeprazole for the treat-
ment of arthritic patients with high risks. METHODS:
A decision tree was designed to analyze the economic 
and clinical outcomes of a randomized controlled clinical
trial. Two hundred and eighty-seven patients with arthri-
tis and active ulcer bleeding were recruited. After ulcer
healing had been conﬁrmed, the patients were random-
ized to receive either celecoxib 200mg twice daily or
diclofenac twice daily plus 20mg of omeprazole daily for
6 months. The clinical outcome was incidence of ulcer
bleeding. The healthcare resource consumption associ-
ated with study patients was retrieved from the trial case
reports. The direct medical costs were estimated based
upon symptom-driven healthcare resources utilization.
The study was performed from the perspective of a public
health organization in Hong Kong. RESULTS: Seven out
of 144 patients (4.9%) in the celecoxib group and 9 
out of 143 patients (6.3%) in the diclofenac group 
experienced ulcer bleeding. The mean cost for manage-
ment of ulcer bleeding was HKD19,434 (95% CI:
HKD10,950–27,918) (1US = 7.8HKD). The mean total
cost of routine follow-up and differential diagnosis
during study period for patients in the celecoxib 
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group and diclofenac group were HKD10,211 (95% 
CI: HKD9,807–10,615) and HKD11,505 (95% CI:
HKD11,140–11,870), respectively. The results of the
decision tree analysis showed that the direct cost per
patient was HKD11,155 and HKD12,729 for the cele-
coxib and diclofenac groups, respectively. No threshold
value was identiﬁed by sensitivity analysis. CONCLU-
SION: Based on the analysis of the data obtained from a
large clinical trial, celecoxib was as safe as diclofenac with
omeprazole but appeared to cost less for the treatment of
arthritis in a group of high-risk Chinese patients.
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OBJECTIVE: Given the sensitivity of ﬁndings to the gas-
troprotective agent (GPA) rate assumption used in COX-
2 cost-effectiveness models, the purpose of this study is
to verify the GPA rate assumptions and to re-estimate
model outcomes from one published COX-2 cost-
effectiveness study using GPA rates from actual practice.
METHODS: Prescription and medical claims data from
a large preferred provider organization (PPO) located in
the Midwest were used to estimate GPA rates within 
three samples of adult patients new to non-selective non-
steroidal antiinﬂammatory drugs (NSAIDs) and COX-2
therapy: all new NSAID users, new NSAID users with a
diagnosis of arthritis, and a cohort matched on GI risk.
Members were continuously eligible over the study period
of January 1, 1999 through May 31, 2001. RESULTS:
Of the more than 319,000 members with at least 1 day
of eligibility, the number of members meeting inclusion
criteria in each of the three samples were 1,900 for new
NSAID users, 289 with a diagnosis of arthritis, and 1,386
in the matched cohort sample. GPA estimates for non-
selective NSAID and COX-2 users were consistent across
all 3 samples with COX-2 GPA rates of 22%, 21% and
20% and nonselective NSAID GPA rates of 15%, 15%,
and 18%, for new NSAID users, those with a diagnosis
of arthritis, and the matched cohort, respectively. Re-
estimation of the cost-effectiveness model using the most
conservative GPA rates increased the cost per year of life
saved for COX-2s from $18,614 to over $100,000.
CONCLUSIONS: Contrary to COX-2 cost-effectiveness
model assumptions, the rate of GPA use is positive and
marginally higher among COX-2 users than among non-
selective NSAID users. These ﬁndings call into question
the validity of assumptions regarding patterns of use
when made prior to a product’s use in the real world.
Given these ﬁndings, a re-evaluation of the cost-
effectiveness of COX-2 therapies should be considered.
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OBJECTIVES: In Australia, hormone replacement
therapy (HRT) is the standard therapy for reducing 
fracture risk in postmenopausal women with no previous
fracture. Therapies like bisphosphonates, calcitriol and
raloxifene are used in women with radiographically
deﬁned fracture resulting from minimal trauma. The
results of the Women’s Health Initiative study point to the
need, however, to assess the cost-effectiveness of newer
agents in preventing fracture in osteoporotic women
without prior fracture. This study aimed to assess the
cost-effectiveness of raloxifene in preventing osteoporotic
fractures in such a population. METHODS: A Markov
model was developed to compare raloxifene with HRT
and with alendronate in osteoporotic women with no
prior fracture. Relative efﬁcacy assumptions in the model
were based solely on the results of randomised controlled
trials (MORE, FIT-II, WHI), while transition probabili-
ties and downstream fracture effects were taken from a
range of literature. Primary outcomes included vertebral
fractures, non-vertebral fractures, breast cancer and car-
diovascular disease in a cohort with a low bone mineral
density and an average age of 65 years. The model 
contained 12 discrete states and yielded costs per 
quality-adjusted life-year (QALY). Limited memory was
incorporated into the model by separating each fracture
health state into two states, representing the ﬁrst and sub-
sequent years after fracture. The model ran for a 30-year
period, but therapy was assumed to continue for only 5
years, after which transition probabilities reverted to
values associated with no treatment. RESULTS: The
incremental cost per QALY gained with raloxifene treat-
ment compared with HRT in a population of osteo-
porotic women with no prior fracture was $14,506
(US$8,203). In the same population, raloxifene was
found to be more effective and less expensive than 
alendronate. Extensive sensitivity analyses indicated 
these results were robust. CONCLUSION: Raloxifene is
a cost-effective therapy to reduce fracture risk in post-
menopausal osteoporotic women without prior fracture.
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OBJECTIVES: This study investigates compliance with
hormone replacement therapy (HRT), bisphosphonate
